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Monoclonal gammopathy of undetermined signiﬁcance (MGUS) has been most commonly associated with diseases like multiple
myeloma, Waldenstrom’s macroglobulinemia, primary systemic amyloidosis, HIV, and other lymphoproliferative disorders. There
hasbeenanisolatedreportofMGUSinpatientscoinfectedwithHIVandHepatitisB,astheworkbyAmaraetal.in2006.Here,we
report a case of IgA-kappa light chain gammopathy secondary to Hepatitis B infection, which resolved after liver transplantation.
To our knowledge, this is the ﬁrst reported case of M protein spike seen in the context of Hepatitis B infection only.
Copyright © 2009 P. Sreenivasan and S. Nair. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Case
Mr. SD, a 45-year-old Caucasian male, was referred for
evaluationforlivertransplantationbecauseofend-stageliver
disease caused by Hepatitis B. He had been well until six
monthspriortohisinitialvisit,whenhestartedlosingweight
and developed severe fatigue. During the six-month period,
he had lost 25 kilograms.
His past medical history was signiﬁcant for non-
Hodgkin’s lymphoma that was diagnosed eleven years ago.
Hewastreatedwith8cyclesofCHOPchemotherapyandhad
been in remission since then.
On examination, the patient appeared mildly icteric. The
abdomen was soft with some tenderness in the right upper
quadrant and ascites. The spleen was mildly enlarged. The
remainder of the examination was normal. No enlarged
lymph nodes were detected.
Complete blood count showed a leukocyte count of
2500cells/mm3, hemoglobin of 9.8gm/dL, and platelet
count of 29000cells/mm3. His liver function tests were
abnormal with a total bilirubin of 5mg/dL (normal,
0.2–1.2mg/dL), ALT: 361U/L (normal, 17–63U/L), AST:
750IU/L (normal, 15–40U/L), total protein: 15.4g/dL (nor-
mal,6.1–7.9g/dL),albumin:2.9g/dL(normal,3.9–4.8g/dL),
and an INR of 1.9. Serological tests for viral hepatitis were as
follows: Hepatitis B surface antigen positive (HbsAg), Hep-
atitis B surface antibody negative (antiHBs), HBe antigen
negative, HBe antibody positive, IgM antibody to Hepatitis
B core antigen positive, IgG antibody to Hepatitis B core
antigen positive, and HBV DNA 4 150000IU/mL (by PCR).
Antibodies against hepatitis delta virus and hepatitis A
virus were negative. HCV antibody was negative. Hepatitis
C RNA was undetectable. Cytomegalovirus IgG and IgM
were negative. Ebstein Barr virus IgM was negative and
IgG was positive. He had a negative antinuclear antibody
and a negative antismooth muscle antibody. HIV antibody
was negative. Esophagogastroduodenoscopy revealed mild
esophagitis and erythema of the gastric body. The duodenal
biopsies were normal. Colonoscopy was normal. CT scan
and ultrasound examination of the abdomen showed a small
liver with moderate ascites, splenomegaly, patent portal, and
hepatic veins. There were no enlarged lymph nodes on CT
scan. Liver biopsy conﬁrmed cirrhosis from HBV.
The striking elevation in his globulin fraction (12.5g/dL)
was further worked up. Serum protein electrophoresis
showed the presence of a large monoclonal protein spike
(M protein) in the gamma region which on immunoﬁxation
electrophoresis(IFE)wasidentiﬁedtobeIgA-kappatype(see
Figure 1). The IgA levels were increased at 6730mg/dL (ref-
erencerange70–400mg/dL)andtheIgGandIgMlevelswere2 Journal of Transplantation
150 100 50 0
Time in days Time of liver transplant






































Figure 1 :T o t a lp r o t e i na n dI g Al e v e l s .
decreased at 466mg/dL (reference range 700–1600mg/dL)
and25.6mg/dl(referencerange40–320mg/dL),respectively.
Urine was negative for M protein. Cryoglobulins were
negative. Serum viscosity was 3.3 (normal, 1.4–1.8). A
bone marrow biopsy on two separate occasions showed
normocellular bone marrow with less than 2 percent pop-
ulation of plasma cells. The plasma cells were predominantly
kappa light chains on the in situ hybridization. Bone
marrow cytogenetics did not detect any abnormalities. These
results were reproduced on 2 repeat bone marrow biopsies.
Metastatic bone survey showed no myelomatous lesions. Full
bodypositronemissiontomography(PET)scanandCTscan
were performed, and no focus suspicious for lymphoma or
myeloma or infection was identiﬁed. Whole body MRI was
unremarkable. On retrospective review, the patient had an
elevated total protein (12g/dL) approximately six months
prior to initial visit.
Within thenext fewweeks,the patient continued to dete-
riorate, and he developed worsening ascites with hypona-
tremia. It was clear that the patient had progressive liver
diseasefromchronicHepatitisBwitharelativelyhighMELD
scoreof23,andhewouldbeneﬁtfromalivertransplantation.
Our dilemma before proceeding with liver transplantation
waswhetherhehadanunderlyinghematologicalmalignancy
thatwascausingthemonoclonalgammopathy.Thiswaseven
more relevant given his prior history of lymphoma. We were
also concerned about potential vascular complications after
liver transplant given his increased viscosity. However, due
to his deterioration and absence of any clear-cut evidence of
malignancy, it was decided to place the patient on the liver
transplant wait list. We chose not to anticoagulate him since
he already had an elevated INR.
Anti-HBV therapy was initiated with a combination
of entecavir (0.5mg/day) and tenofovir (300mg/day) to
decrease his HBV DNA to the lowest possible level before
transplantation. However, he was on this antiviral therapy
for less than a month as he received a deceased donor liver
transplant ten days after listing. In the period between listing
and liver transplantation, his bilirubin continued to trend
up from 3.3mg/dL to 4.6mg/dL, and his total protein level
ﬂuctuated between 12.5g/dL and 13.5g/dL.
Six weeks after his liver transplant, his HBV DNA level
was undetectable. He cleared his Hepatitis B surface antigen
four months after transplant. His IgA levels normalized.
As per standard protocol in our institution, he received
two doses of rabbit antithymocyte globulin at 1.5mg/kg
during the time of transplant and on postoperative day
2. He also received tacrolimus and mycophenolate mofetil
for 3 months. Subsequently, the mycophenolate mofetil was
withdrawn, and he is currently on tacrolimus monotherapy
with trough levels between 3–5mg/mL. He continues to
receive Hepatitis B immunoglobulin infusion every month
along with entecavir (0.5mg/day), and his Hepatitis B
antibody titre has been kept above 300mIU/mL. He is
currently 9 months posttransplant, his total protein levels
range4-5g/Dl,andhehashadnodetectableMproteinspike.
The temporal relation of the liver transplant with disap-
pearance of Hepatitis B surface antigen and normalization of
the monoclonal spike implicates Hepatitis B as the possible
cause of the M protein spike.
2. Discussion
There is very little data and uncertainty regarding the
incidence and natural history of M proteins in a person with
Hepatitis B. It has been suggested that the immunological
response elicited against Hepatitis B virus in the host
rather than the direct cytopathic eﬀect of the virus may be
the basis for the pathogenesis of hepatic and nonhepatic
manifestations [2]. Hepatitis B virus seems particularly well
suited to initiate a chronic immune disease because of its
tendency to persist in spite of a good immune response.
This may cause clonal expansion of the immunoglobulin
secreting cells and may explain the above phenomenon.
Alternately, the M protein spike could represent increased
serum immunoconglutinin titres. It has been previously
suggested that elevated serum immunoconglutinin titers in
patients with acute and chronic hepatitis B virus infection
may represent a physiological autoimmune response to
HbsAg/anti-HBs immune complexes [3]. Although our
patient did not have the anti-HBs antibody, it has been
suggested that in the light of massive antigenemia present
in chronic HbsAg carriers, it is possible that anti-HBs exists
in the form of HbsAg/anti-HBs immune complexes. This
would make it diﬃcult to detect anti-HBs in serum samples
by conventional serological methods [4].
There were several intriguing aspects to this patient.
T h ep r i m a r yi s s u ew a sw h e t h e rh ew a se l i g i b l ef o rl i v e r
transplantation in the presence of an increasing M protein.
Thefactthathehadlymphoma10yearsagocomplicatedthis
evaluation. Additionally, an association between Hepatitis B
infection and non-Hodgkin’s lymphoma has been previously
described [5]. However, he had had regular follow-ups
every six months after remission of lymphoma, and also
his malignancy workup prior to transplant was negative.
Moreover, the M protein spike was noticed only 6 months
prior to transplant and this coincided with the elevation
of his liver function tests. Surprisingly, his IgM antibody
to Hepatitis B core antigen was positive, as was his total
core antibody. He did have active hepatitis and this can
be deduced by the fact that he had an ALT level that wasJournal of Transplantation 3
10 times the upper limits of normal; his explanted liver
showed signiﬁcant inﬂammatory activity. His biopsy also
revealed frank cirrhosis. By putting all this together, it was
felt that most likely he had a ﬂare of his chronic HBV, which
might have triggered the elevation in M protein.
Because of his elevated M protein and an urgent need for
livertransplantation,wedecidedtoinitiatedualtherapywith
a nucleoside (entecavir) and nucleotide (tenofovir) analogue
to decrease his HBV DNA. However, he was on therapy
less than a month before a suitable organ became available.
We decided to accept the organ because of high MELD
score rather than to wait for HBV DNA disappearance.
Since we were planning to continue therapy posttransplant
along with HBIG (target anti-HBs titers >500IU/mL ﬁrst
three months and levels of >300IU/mL after three months),
we believed that the risk of recurrence of HBV was very
small. Unfortunately in the time period before the transplant
and after initiation of antiviral therapy, we failed to follow
his IgA levels and HBV DNA levels. However, his protein
levels remained unchanged suggesting that there may have
been very little change in his gammopathy, and this is not
surprising given the fact that nucleos(t)ide therapy seldom
leads to HBsAg clearance in that time frame.
After liver transplantation and with clearance of the
Hepatitis B surface antigen, the M protein levels became
normal. There are two potential explanations for the dis-
appearance of the M protein spike. One and the most
likely reason is the removal of antigen source with native
hepatectomy. His Hepatitis B surface antigen, M protein,
and total protein levels remain within normal limits 1 year
after transplantation. The second possibility is the impact
of thymocyte, given at the time of transplant, on plasma
cells. Antithymocyte globulin has been used in treatment of
plasma cell dyscrasias [6] due to its activity against several
plasma cell antigens. This is less likely in our patient because
thymocyte globulin was used only as induction therapy at
the time of transplantation. The elimination half time of
thymoglobulin is 2-3 days and is unlikely that its eﬀect
on plasma cell is sustained for a year [6]. In conclusion,
this case demonstrates that monoclonal gammopathy can
be associated with chronic Hepatitis B infection and can be
eliminated after successful transplantation.
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